In addition, the concurrent inhibition of mTOR and WEE1 has been demonstrated to elicit robust synergistic cytotoxic effects in NSCLC cell lines harboring KRAS mutations. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.